On 2017 Feb 11, Dong Wang commented:
Reply to Martin Mayer, MS, PA-C
Authors: Dong D. Wang, MD, ScD and Frank B. Hu, MD, PhD
From the Departments of Nutrition (DDW and FBH) and Epidemiology (FBH), Harvard T. H. Chan School of Public Health, Boston, MA; The Channing Division for Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (FBH)
We agree with Mr. Mayer that ‘well-designed, well-executed randomized controlled trials (RCTs)’ can provide strong evidence for the causal effect between dietary fatty acids and mortality. However, because of multiple methodological limitations, e.g., poor compliance and high drop-out rate, decades-long RCTs testing effects of dietary interventions on hard endpoints, such as cardiovascular disease (CVD) incidence and mortality, are extremely difficult to conduct [1]. High cost and ethical considerations are additional challenges for conducting such a RCT. Further, the notion that RCTs are ‘confounding-free’ is only held when there are low rates of drop out and high degree of compliance. In most large-scale long-term RCTs, biases may occur after baseline randomization due to differential adherence to assigned treatment regimens, differential loss to follow-up, and other differences between comparison groups [2]. In addition, our findings based on prospective cohorts are consistent with effects of replacing saturated fatty acid (SFA) by polyunsaturated fatty acid (PUFA) on both blood lipids [3] and cardiovascular disease [4] from RCTs. Thus, in most situations, large prospective cohort studies of hard clinical endpoints, when well designed and interpreted in the context smaller RCTs on intermediate endpoints such as blood lipids, can provide the best available evidence to inform dietary recommendations. One such example is trans fat. Large epidemiologic studies like ours found a consistent positive association between trans fat intake and risk of cardiovascular disease. Meanwhile, small RCTs found that trans fatty acids increase total and LDL cholesterol. The combination of these two types of evidence has led to the policies that result in food labeling and banning in the food supply [5].
Citing Nissen and Ioannidis’ attacks on methodological issues of nutritional epidemiology [6, 7], Mr. Mayer questioned the validity of the food frequency questionnaires (FFQs) in assessing dietary intakes. However, Nissen and Ioannidis’ viewpoints and Mr. Mayer’s question simply reflect lack of understanding of the basic methodology of nutritional epidemiology and human nutrition research. In contrary to Mr. Mayer’s claim, our food frequency questionnaires (FFQs) have been demonstrated to be a useful and valid dietary assessment instrument to measure long-term usual dietary intake in well-conducted epidemiological studies [1, 8]. The validity of our FFQs against multiple-day diet records and biomarkers in the validation studies has been extensively documented [8]. For example, the correlations between energy-adjusted intakes assessed by the 1986 FFQ and the mean of multiple weighed 1-week dietary records collected in 1980 and 1986, corrected for variation in the records, were 0.67 for total fat, 0.70 for SFA, 0.69 for MUFA, and 0.64 for PUFA. [8] Correlations increased when the mean of 3 FFQs (1980, 1984, and 1986) was used; for example, for SFAs the correlation was 0.95. The correlation between dietary fatty acid intake assessed by the FFQ and the composition of fatty acids in adipose tissue were 0.51 for TFA, 0.35 for LA, and 0.48 for long-chain n-3 PUFA in NHS, [9] and 0.29 for TFA, 0.48 for LA, and 0.47 for EPA in HPFS. Moreover, adjustment for total energy intake, along with use of cumulative average intake calculated from many repeated FFQs, further dampens the measurement errors and improves the validity [8].
By pointing out that our study population was ‘exclusively health care professionals with noteworthy exclusion criteria’, Mr. Mayer questioned the generalizability of our findings. However, the effect estimates represent the underlying physiological mechanisms relating fatty acid intake to mortality that are generally applicable to other populations. In addition, for the estimated effect of substituting SFA by PUFA, the hazard ratio (HR) of CVD mortality in our study (0.72, 95% CI, 0.65-0.80) is similar to the HR of coronary death (0.74, 95% CI, 0.61-0.89) estimated from a pooled analysis including 11 cohorts with diverse sociodemographic characteristics, which further support the generalizability of our findings [10]. Because our study intended to mimic a primary prevention setting, we excluded participants with major chronic diseases, including CVD, cancer and diabetes, at baseline. In contrary to Mr. Mayer’s assertion, applying these exclusion criteria, our study produced more generalizable findings to inform dietary recommendations for primary prevention of disease outcomes in the general population.
Mr. Mayer criticized our use of HR, a ratio measure, and claimed only reporting HRs is ‘considerably less informative and can contribute to distorted appraisal of research findings’. These assertions are unfounded. Both ratio and difference measurements have their own merits and usefulness. Difference measures are measures of the public health and clinically relevant effect of exposure, whereas relative measures are measures of the biological strength of the association between an exposure and disease outcome. Therefore, reporting HRs is compatible with the objective of our study, i.e., to examine the associations of specific dietary fats with total and cause-specific mortality. From a technical perspective, HR is the default outputs estimated by the multiplicative Cox proportional hazards model, the most robust and widely applied statistical model for time-to-event data. It is important to note that HRs can be compared across different studies and populations, whereas difference measures are difficult to compare because of different baseline risk in different populations.
In summary, our study provided strong evidence because of the solid study design, such as many repeated measurements of diet, validated measurement methods and high follow-up rates over decades, and sophisticated statistical analysis, i.e., extensive adjustment for a large number of potential confounding factors. Our findings are consistent with other high-quality evidence from both observational cohort studies and RCTs [3, 4, 10] and meet multiple key Bradford-Hill criteria, including the strength and consistency of the evidence, biological plausibility, temporal relationships and experimental evidence on intermediate biomarkers.
Conflict of interest: None
Reference
[1] Satija, A., et al., Advances in nutrition, 2015. 6(1): p. 5-18.
[2] Manson, J.E., et al., Jama, 2016. 315(21): p. 2273-4.
[3] Mensink, R.P., et al., The American journal of clinical nutrition, 2003. 77(5): p. 1146-55.
[4] Mozaffarian, D., et al., PLoS Med, 2010. 7(3): p. e1000252.
[5] National Conference of State Legislatures.: http://www.ncsl.org/issues-research/health/trans-fat-and-menu-labeling-legislation.aspx.
[6] Ioannidis, J.P., BMJ, 2013. 347: p. f6698.
[7] Nissen, S.E., Annals of internal medicine, 2016. 164(8): p. 558-559.
[8] Willett, W.C., Nutritional epidemiology 2013, Oxford University Press.
[9] London, S.J., et al., The American journal of clinical nutrition, 1991. 54(2): p. 340-5.
[10] Jakobsen, M.U., et al., The American journal of clinical nutrition, 2009. 89(5): p. 1425-32.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.